Galapagos (NASDAQ:GLPG) Rating Increased to Hold at Wall Street Zen

Galapagos (NASDAQ:GLPG) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Other equities research analysts also recently issued research reports about the company. Royal Bank Of Canada increased their price objective on Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Leerink Partners set a $40.00 target price on Galapagos and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Galapagos in a report on Tuesday, August 5th. Leerink Partnrs raised Galapagos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Galapagos in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $31.33.

Galapagos Price Performance

NASDAQ GLPG opened at $30.66 on Friday. Galapagos has a 1 year low of $22.36 and a 1 year high of $37.78. The stock has a market capitalization of $2.02 billion, a PE ratio of -19.53 and a beta of 0.23. The company’s 50 day simple moving average is $32.72 and its two-hundred day simple moving average is $31.01.

Institutional Trading of Galapagos

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Galapagos by 2.1% during the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock worth $1,072,000 after acquiring an additional 643 shares in the last quarter. GAMMA Investing LLC raised its position in Galapagos by 79.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 652 shares during the period. Two Sigma Investments LP raised its position in Galapagos by 3.7% in the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 800 shares during the period. State of Wyoming bought a new stake in Galapagos in the second quarter worth $28,000. Finally, American Century Companies Inc. boosted its position in Galapagos by 7.7% during the first quarter. American Century Companies Inc. now owns 27,839 shares of the biotechnology company’s stock valued at $699,000 after buying an additional 1,987 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.